Insider Trading Alert - BRT, TNAV And HZNP Traded By Insiders

Yesterday, Feb. 29, 2016, 88 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $499.80 to $7,375,492.00.

Highlighted Stocks Traded by Insiders:

BRT Realty (BRT) - FREE Research Report

Gould Investors L P, who is 10% Owner at BRT Realty, bought 76,684 shares at $6.26 on Feb. 29, 2016. Following this transaction, the 10% Owner owned 3.0 million shares meaning that the stake was boosted by 2.64% with the 76,684-share transaction.

The shares most recently traded at $6.45, up $0.19, or 2.95% since the insider transaction. Historical insider transactions for BRT Realty go as follows:

  • 4-Week # shares bought: 2,932
  • 4-Week # shares sold: 1,850
  • 12-Week # shares bought: 2,932
  • 12-Week # shares sold: 1,850
  • 24-Week # shares bought: 4,432
  • 24-Week # shares sold: 1,850

The average volume for BRT Realty has been 20,400 shares per day over the past 30 days. BRT Realty has a market cap of $92.4 million and is part of the financial sector and real estate industry. Shares are up 1.74% year-to-date as of the close of trading on Monday.

BRT Realty Trust, a real estate investment trust (REIT), owns, operates, and develops multi-family properties in the United States. It operates through two segments, Multi-Family Real Estate and Other Real Estate. Currently, there are no analysts who rate BRT Realty a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BRT - FREE

TheStreet Quant Ratings rates BRT Realty as a sell. The company's weaknesses can be seen in multiple areas, such as its poor profit margins, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full BRT Realty Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Telenav (TNAV) - FREE Research Report

Strambi Michael, who is Cfo at Telenav, sold 10,000 shares at $5.82 on Feb. 29, 2016. Following this transaction, the Cfo owned 30,528 shares meaning that the stake was reduced by 24.67% with the 10,000-share transaction.

The shares most recently traded at $6.18, up $0.36, or 5.75% since the insider transaction. Historical insider transactions for Telenav go as follows:

  • 4-Week # shares sold: 9,404
  • 12-Week # shares sold: 9,404
  • 24-Week # shares sold: 9,404

The average volume for Telenav has been 144,100 shares per day over the past 30 days. Telenav has a market cap of $243.7 million and is part of the technology sector and internet industry. Shares are up 4.75% year-to-date as of the close of trading on Monday.

Telenav, Inc. provides location-based platform services in the United States and internationally. The company operates through three segments: Automotive, Advertising, and Mobile Navigation. Currently, there are 3 analysts who rate Telenav a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TNAV - FREE

TheStreet Quant Ratings rates Telenav as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Telenav Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Horizon Pharma (HZNP) - FREE Research Report

Sherman Jeffrey W, who is EVP and Chief Medical Officer at Horizon Pharma, sold 4,100 shares at $20.00 on Feb. 29, 2016. Following this transaction, the EVP and Chief Medical Officer owned 149,648 shares meaning that the stake was reduced by 2.67% with the 4,100-share transaction.

The shares most recently traded at $16.22, down $3.78, or 23.3% since the insider transaction. Historical insider transactions for Horizon Pharma go as follows:

  • 4-Week # shares sold: 7,750
  • 12-Week # shares sold: 7,750
  • 24-Week # shares bought: 6,000
  • 24-Week # shares sold: 7,750

The average volume for Horizon Pharma has been 3.7 million shares per day over the past 30 days. Horizon Pharma has a market cap of $3.2 billion and is part of the health care sector and drugs industry. Shares are down 20.82% year-to-date as of the close of trading on Monday.

Horizon Pharma plc, a specialty biopharmaceutical company, engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. The company has a P/E ratio of 164.9. Currently, there are 6 analysts who rate Horizon Pharma a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HZNP - FREE

TheStreet Quant Ratings rates Horizon Pharma as a sell. The area that we feel has been the company's primary weakness has been its feeble growth in its earnings per share. Get the full Horizon Pharma Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Texas Instruments CEO Resigns After Violating Code of Conduct

Texas Instruments CEO Resigns After Violating Code of Conduct

Video: Here's How Goldman Sachs May Change Under David Solomon

Video: Here's How Goldman Sachs May Change Under David Solomon

Abbott's Capital Flexibility in Focus Ahead of Earnings Release

Abbott's Capital Flexibility in Focus Ahead of Earnings Release

Markets Close Higher After Fed Chair Powell's Capitol Hill Testimony

Markets Close Higher After Fed Chair Powell's Capitol Hill Testimony

Boeing Inks Freighter Deal, Lifts Industry Demand Forecast

Boeing Inks Freighter Deal, Lifts Industry Demand Forecast